The United States Patent and Trademark Office (USPTO) has officially registered the trademark IMPRIMISRX, identified by TM86527531, for services related to pharmaceutical compounding. This registration signifies the USPTO's approval of the mark for use in commerce for these specific services.

While this is a trademark registration and not a regulatory rule, entities operating in pharmaceutical compounding should be aware of this registered mark. Companies should ensure their own branding and service offerings do not infringe upon IMPRIMISRX. No specific compliance actions are mandated by this trademark registration itself, but it reinforces the importance of trademark diligence in the pharmaceutical sector.